Letter to the Editor
IVIG and graft coronary artery disease: A potentially deadly combination in pediatric heart transplant recipients
Elizabeth Dorwart,
Elizabeth Dorwart
Department of Pediatrics, Stanford University, Palo Alto, CA, USA
Search for more papers by this author Nancy McDonald,
Nancy McDonald
Pediatric Heart Transplantation, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA
Search for more papers by this author Katsuhide Maeda,
Katsuhide Maeda
Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA, USA
Search for more papers by this author David N. Rosenthal,
David N. Rosenthal
Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, USA
Search for more papers by this author Seth A. Hollander,
Seth A. Hollander
Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, USA
Search for more papers by this author
Elizabeth Dorwart,
Elizabeth Dorwart
Department of Pediatrics, Stanford University, Palo Alto, CA, USA
Search for more papers by this author Nancy McDonald,
Nancy McDonald
Pediatric Heart Transplantation, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA
Search for more papers by this author Katsuhide Maeda,
Katsuhide Maeda
Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA, USA
Search for more papers by this author David N. Rosenthal,
David N. Rosenthal
Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, USA
Search for more papers by this author Seth A. Hollander,
Seth A. Hollander
Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, USA
Search for more papers by this author
First published: 21 October 2014
No abstract is available for this article.
References
- 1Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIG) – A potential tool for transplantation of immunized patients. Transplantation 1993: 56: 335–337.
- 2Elkayam O, Paran D, Milo R, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 2000: 59: 77–80.
- 3Baxley A, Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2011: 11: 1663–1667.
- 4Cherin P, Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs 2010: 24: 211–223.
- 5Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007: 6: 257–259.
